Moxifloxacin Impurity C (EP); 8-Ethoxymoxifloxacin

GA01092

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer. Fluoroquinolones are broad-spectrum antibiotics, effective for both gram-negative and gram-positive bacteri, that play an important role in treatment of serious bacterial infections, especially hospital-acquired infections and others in which resistance to older antibacterial classes is suspected. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, thereby inhibiting cell replication. Moxifloxacin is used to treat certain infections such as pneumonia, bronchitis, and sinus, skin, and abdominal (stomach area) infections caused by bacteria. It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment.

We have successfully synthesized standards of the Moxifloxacin. This will be of interest to pharmaceutical companies and analytical labs.